Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.82
-0.26-5.22%
Last update: Apr 23, 10:43 AM
Myriad Genetics Inc Analyst Ratings
MYGNNASDAQ
Myriad Genetics Analyst Ratings and Price Targets | NASDAQ:MYGN | Benzinga
Myriad Genetics Inc has a consensus price target of $14.34 based on the ratings of 18 analysts. The high is $29 issued by Craig-Hallum on February 12, 2025. The low is $6 issued by UBS on February 24, 2026. The 3 most-recent analyst ratings were released by UBS, Wells Fargo, and Piper Sandler on February 24, 2026, February 24, 2026, and November 11, 2025, respectively. With an average price target of $6.83 between UBS, Wells Fargo, and Piper Sandler, there's an implied 41.92% upside for Myriad Genetics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
Wells Fargo
Piper Sandler
TD Cowen
Scotiabank
1calculated from analyst ratings
Analyst Ratings for Myriad Genetics
Loading calendar...
FAQ
What is the target price for Myriad Genetics (MYGN) stock?
The latest price target for Myriad Genetics (NASDAQ:MYGN) was reported by UBS on February 24, 2026. The analyst firm set a price target for $6.00 expecting MYGN to rise to within 12 months (a possible 24.61% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Myriad Genetics (MYGN)?
The latest analyst rating for Myriad Genetics (NASDAQ:MYGN) was provided by UBS, and Myriad Genetics maintained their neutral rating.
When was the last upgrade for Myriad Genetics (MYGN)?
The last upgrade for Myriad Genetics Inc happened on March 12, 2025 when Piper Sandler raised their price target to $12.5. Piper Sandler previously had a neutral for Myriad Genetics Inc.
When was the last downgrade for Myriad Genetics (MYGN)?
The last downgrade for Myriad Genetics Inc happened on May 21, 2025 when Scotiabank changed their price target from $20 to $6 for Myriad Genetics Inc.
When is the next analyst rating going to be posted or updated for Myriad Genetics (MYGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Myriad Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Myriad Genetics was filed on February 24, 2026 so you should expect the next rating to be made available sometime around February 24, 2027.
Is the Analyst Rating Myriad Genetics (MYGN) correct?
While ratings are subjective and will change, the latest Myriad Genetics (MYGN) rating was a maintained with a price target of $8.00 to $6.00. The current price Myriad Genetics (MYGN) is trading at is $4.82, which is out of the analyst’s predicted range.
